Table 3.
Relationship types and classes involved in the relationship.
| Plain English Description | Concept 1 Class | Relationship Type | Concept 2 Class | Axioms |
|---|---|---|---|---|
| Generic class hierarchy* | (Multiple) | Is a | (Multiple) | 2,214 |
| Generic external mapping* | (Multiple) | Maps to | (Multiple) | 664 |
| Evidence to support use | (Multiple) | Was studied in | Study | 18,076 |
| Biomarker-specific disease subtype** | BioCondition | Is bio subclass | Condition | 21 |
| Brand name(s)* | Component | Has brand name | Brand Name | 2,140 |
| Drug prescription signetur | Component | Has sig | Sig or Sig Stub | 6,370 |
| Drug route(s)* | Component | May have route | Route | 624 |
| Year of FDA approval | Component | Was FDA approved yr | Year | 390 |
| Middle author | Reference | Has middle author | Author | 68,288 |
| First author | Reference | Has first author | Author | 5,507 |
| Last author | Reference | Has last author | Author | 5,479 |
| Journal of publication | Reference | Was published in | Journal | 5,642 |
| PubMed URL | Reference | Has PMID | PubMedURL | 5,646 |
| Reference title | Reference | Has title | ReferenceTitle | 5,653 |
| Reference URL | Reference | Has URL | ReferenceURL | 5,693 |
| Year of Publication | Reference | Was published year | Year | 5,457 |
| Biomarker-specific regimen** | Regimen | Has bioaccepted use | BioCondition | 167 |
| Antineoplastic interventions* | Regimen | Has antineoplastic | Component | 4,219 |
| Supportive interventions* | Regimen | Has supportive med | Component | 1,258 |
| Immune suppressing interventions* | Regimen | Has immunosuppressor | Component | 165 |
| Local interventions, including CNS therapy* | Regimen | Has local therapy | Component | 134 |
| Episode context of treatment* | Regimen | Has context | Context | 2,487 |
| Disease context of treatment** | Regimen | Has accepted use | Condition | 4,087 |
| Current Regimen** | Regimen | Is current in | Condition | 2,248 |
| Historical Regimen** | Regimen | Is historical in | Condition | 368 |
| Link to preceding treatment(s)** | Regimen | Can be preceded by | Regimen or Regimen Stub | 969 |
| Link to subsequent treatment(s)** | Regimen | Can be followed by | Regimen or Regimen Stub | 868 |
| Direct comparison within an RCT | Regimen | Has been compared to | Regimen or Regimen Stub | 3,872 |
| Regimen type* | Regimen | Has regimen type | Regimen type | 1,688 |
| Antineoplastic interventions (RxNorm)*+ | Regimen | Has antineopl Rx | RxNorm Ingredient | 4,018 |
| Supportive interventions (RxNorm)*+ | Regimen | Has support med Rx | RxNorm Ingredient | 1,001 |
| Immune suppressing interventions (RxNorm)*+ | Regimen | Has immunosuppr Rx | RxNorm Ingredient | 143 |
| Local interventions, including CNS therapy (RxNorm)*+ | Regimen | Has local therap Rx | RxNorm Ingredient | 130 |
| Reference | Study | Has reference | Reference | 5,648 |
| Study group | Study | Has study group | Study Group | 1,147 |
| Study’s short name | Study | Has study short name | Study name short | 4,787 |
| Total relationships: | 177,268 | |||
*
These relationship types are included in the first public OHDSI release
**
These relationship types will be included in the second public OHDSI release
+
These relationship types are named mapping relationships to external vocabularies